Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02309723|
Recruitment Status : Completed
First Posted : December 5, 2014
Results First Posted : April 10, 2017
Last Update Posted : April 10, 2017
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease Mild Cognitive Impairment||Device: Beta amyloid imaging||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||315 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Survey of Clinicians to Assess the Influence of Beta-amyloid Imagining Information on the Diagnosis and Management of Hypothetical Patients With Cognitive Complaints|
|Study Start Date :||September 2013|
|Actual Primary Completion Date :||September 2013|
|Actual Study Completion Date :||November 2013|
Experimental: Positive beta amyloid findings
Beta amyloid imaging results indicated a positive finding.
Device: Beta amyloid imaging
Experimental: Negative beta amyloid findings
Beta amyloid imaging results indicated a negative finding.
Device: Beta amyloid imaging
|No Intervention: No beta amyloid information|
- Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss [ Time Frame: Online Survey - completion during the estimated 2-3 month field period ]Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint.
- Likelihood of Recommending a Medication Indicated for Alzheimer's Disease [ Time Frame: Online Survey - completion during the estimated 2-3 month field period ]Proportion of respondents who recommend a medication indicated for the treatment of Alzheimer's Disease, including Acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, Typical antipsychotics - e.g., Chlorpromazine (Thorazine), Haloperidol (Haldol), Atypical antipsychotics - e.g., Clozapine (Clozaril), Risperidone (Risperdal), Antidepressant - e.g., Citalopram (Celexa), Venlafaxine (Effexor), Antianxiety agent - e.g. Benzodiazepines, Buspirone (Buspar).
- Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures [ Time Frame: Online Survey - completion during the estimated 2-3 month field period ]Proportion of respondents who recommend that the patient's spouse take actions that would be appropriate if the patient has Alzheimer's disease, including: (1) discussion of advance care planning, (2) monitoring of patient's finances, (3) assessment of how compatible the patient's job is with his conditions, (4) the initiation of precautions to ensure the patient is properly taking his medications to manage hypertension and hyperlipidemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02309723
|United States, Massachusetts|
|Tufts Medical Center|
|Boston, Massachusetts, United States, 02111|
|Study Director:||Joshua T. Cohen, Ph.D||Tufts Medical Center|
|Principal Investigator:||Peter J Neumann, ScD||Tufts Medical Center|